Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation.
Why the study?
Does BN52021 (a PAF antagonist) inhibit in vivo platelet aggregation and cyclic flow variations in animal models of arterial stenosis?
Population
Animal models of arterial stenosis and endothelial injury
Comparison
BN52021 up to 1.2 mg/kg intravenously vs Baseline cyclic flow variations
Design
Preclinical
Follow-up
Up to 8 hours
Authors
Discussion
Loading...
Member takes
Implication
Supports PAF mediation of platelet aggregation post-injury; leaves open clinical translation of antagonists.
Structured PICO
Does BN52021 (a PAF antagonist) inhibit in vivo platelet aggregation and cyclic flow variations in animal models of arterial stenosis?
P
Population
Animal models of arterial stenosis and endothelial injury (12 rabbits with carotid artery stenosis, 35 dogs with coronary artery stenosis)
I
Intervention
BN52021 (platelet activating factor antagonist) up to 1.2 mg/kg intravenously
C
Comparator
Baseline cyclic flow variations (within-subject comparison)
O
Outcome
Inhibition of cyclic flow variations (CFVs)surrogate
Platelet activating factor mediates in vivo platelet aggregation, particularly following leukocyte infiltration of the arterial wall, suggesting PAF antagonists may have potential as antiplatelet agents.
Cite This Study
Golino et al. (1993) studied this question.